<DOC>
	<DOCNO>NCT01145352</DOCNO>
	<brief_summary>This surveillance conduct survey following post market drug utilization patient administrate ENBREL treatment active polyarticular JIA . 1 . Primary Occurrence status Adverse Events ; incidence adverse event , serious adverse event 2 . Secondary Factors affect safety confirm efficacy DAS28 .</brief_summary>
	<brief_title>Enbrel-Juvenile Idiopathic Arthritis ( JIA ) Use Results Survey All-Case Surveillance</brief_title>
	<detailed_description>All patient administrate ENBREL active polyarticular juvenile idiopathic arthritis register period ( 2.5 year ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients active polyarticular JIA ( restrict case lack effect treatment ) enrollment period ( 2.5years ) . Patients receive Enbrel JIA diagnose qualified physician . Age 5 16 year Patients administer ENBREL</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Enbrel-JIA</keyword>
</DOC>